Abstracts tagged "Adalimumab and juvenile arthritis"

Abstract Number: 764 • 2012 ACR/ARHP Annual Meeting
The Impact of Adalimumab On Growth in Patients with Juvenile Idiopathic Arthritis
D. J. Lovell¹, Nicolino Ruperto², Katerina Jarosova³, Dana Nemcova⁴, Veronika Vargova³, Hartmut Michels³, Elizabeth Chalom⁵, Norman Ilowite⁵, Carine Wouters⁶, Hermine Brunner⁷, Karolyn Kracht⁸, Hartmut Kupper⁹, Edward Giannini⁵, Alberto Martini¹⁰ and Neelufar Mozaffarian¹¹, ¹Cincinnati Children's Hospital, Cincinnati, OH, ²Paediatric Rheumatology International Trials Organisation–IRCCS [PRINTO], Genova, Italy, ³PRINTO, Gaslini Institute, Genova, Italy, ⁴Pediatric Rheumatology Unit, Department of Pediatrics and Adolescent Medicine, General University Hospital in Prague, Prague, Czech Republic, ⁵PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁶PRINTO, Genoa, Italy, ⁷PRCSG, Cincinnati Children’s Hospital Medical Center, Genova, Italy, ⁸Abbott, Abbott, Abbott Park, IL, ⁹Immunology Development, Abbott GmbH and Co. KG, Ludwigshafen, Germany, ¹⁰Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, ¹¹Abbott, Abbott Park, IL
Background/Purpose: Children with juvenile idiopathic arthritis (JIA) often exhibit growth impairments. Treatment with adalimumab (ADA) has been shown to be safe and effective in JIA…
Abstract Number: 1148 • 2012 ACR/ARHP Annual Meeting
Adalimumab – Effective Control under Refractory JIA Associated Uveitis
Ekaterina Alekseeva¹, Elena Mitenko², Tatyana Bzarova², Saniya Valieva², Kseniya Isayeva², Alexandra Chomakhidze², Evgeniya Chistyakova², Tatyana Sleptsova² and Rina Denisova², ¹PRINTO, Genoa, Italy, ²Rheumatology, Scientific Center of Children's Health, Moscow, Russia
Background/Purpose: Treatment of juvenile idiopathic arthritis (JIA)–associated uveitis is one of the serious problems of paediatric rheumatology. JIA associated uveitis often is refractory to MTX,…
Abstract Number: 1678 • 2012 ACR/ARHP Annual Meeting
Safety and Efficacy of Adalimumab in Children with Active Polyarticular Juvenile Idiopathic Arthritis Aged 2 to <4 Years or ≥4 Years Weighing <15 Kg
Daniel J. Kingsbury¹, Pierre Quartier², Gina Patel³, Vipin Arora⁴, Hartmut Kupper⁵ and Neelufar Mozaffarian³, ¹Randall Children's Hospital at Legacy Emanuel, Portland, OR, ²Unite d'Immuno-Hematologie et Rhumatologie Pediatriques, Paris, France, ³Abbott, Abbott Park, IL, ⁴Health Outcomes Research, Abbott, Abbott Park, IL, ⁵Immunology Development, Abbott GmbH and Co. KG, Ludwigshafen, Germany
Background/Purpose: Adalimumab (ADA) is approved for use in moderate to severe JIA in patients (pts) ≥4 yrs old in the US, EU,and Japan. ADA has…